{"id":"enn0403-high-dose","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL664","moleculeType":"Small molecule","molecularWeight":"176.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Due to limited information, the exact mechanism of action for ENN0403 is not well understood.","oneSentence":"ENN0403 is a high-dose investigational drug with an unknown mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:50:53.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06708260","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME","status":"RECRUITING","sponsor":"EnnovaBio","startDate":"2024-12-12","conditions":"Diabetic Macular Edema (DME)","enrollment":60},{"nctId":"NCT06632613","phase":"PHASE2","title":"Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery","status":"RECRUITING","sponsor":"EnnovaBio","startDate":"2024-11-05","conditions":"Cardiac Surgery Associated - Acute Kidney Injury","enrollment":200},{"nctId":"NCT05506540","phase":"PHASE1","title":"A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects","status":"COMPLETED","sponsor":"EnnovaBio","startDate":"2021-02-17","conditions":"Healthy","enrollment":69}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":135054,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ENN0403, high dose","genericName":"ENN0403, high dose","companyName":"EnnovaBio","companyId":"ennovabio","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ENN0403 is a small molecule with a modality similar to cotinine, and it has been studied in a Phase 2 clinical trial for Diabetic Macular Edema (DME), as well as other conditions such as Cardiac Surgery Associated - Acute Kidney Injury and in healthy subjects.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}